ONCOLOGY DEVELOPMENT PIPELINE
Novel therapies, new mechanisms
Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide.
Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of approaches across many tumor types. We seek to translate the most innovative science into meaningful breakthrough medicines that redefine life with cancer for patients.
Oncology Pipeline & Trials
Oncology Pipeline as of October 27, 2020
- Discovery Projects
- 15Phase 1
- 9Phase 2
- 6Phase 3
- 3Registration
- Total33
| Compound Name | Indication | Phase | Submission Type | Compound Type |
|---|---|---|---|---|
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Registration Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | 1st Line Urothelial Cancer (Biologic) (E.U.) | Registration | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | 1st Line Non-Small Cell Lung Cancer (Biologic) | Phase 3 | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | 1st Line Merkel Cell Carcinoma (Biologic) | Phase 2 | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | Combo w/Talzenna (talazoparib) for Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors (Biologic) | Phase 2 | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | Combo w/Talzenna (talazoparib) for Solid Tumors with a BRCA or ATM defect (Biologic) | Phase 2 | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | Combo w/CMP-001 for Head and Neck Cancer | Phase 2 | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | Combo w/ Talzenna (talazoparib) and binimetinib for Solid Tumors (Biologic) | Phase 1 | Product Enhancement | Biologic |
Braftovi (encorafinib) + Mektovi (binimetinib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinased inhibitor and MEK inhibitor | BRAF-mutant Metastatic Melanoma Brain Metastasis (ORPHAN - U.S.) | Phase 2 | Product Enhancement | Small Molecule |
Braftovi (encorafinib) + Mektovi (binimetinib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinased inhibitor and MEK inhibitor | 1st line and 2nd line BRAF-mutant Metastatic Non-Small Cell Lung Cancer | Phase 2 | Product Enhancement | Small Molecule |
Braftovi (encorafinib) + Mektovi (binimetinib)+ Erbitux® (cetuximab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinased inhibitor and MEK inhibitor | 1st line BRAF-mutant Metastatic Colorectal Cancer | Phase 2 | Product Enhancement | Small Molecule |
Ibrance (palbociclib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: CDK 4,6 Kinase Inhibitor | ER+/HER2+ Breast Cancer | Phase 3 | Product Enhancement | Small Molecule |
Lorbrena (lorlatinib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: ALK Inhibitor | 1st Line ALK Non-Small Cell Lung Cancer (ORPHAN - U.S.) | Phase 3 | Product Enhancement | Small Molecule |
PF-05082566 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: CD137 Agonist | Combo w/Kite Pharma'sYescarta (axicabtagene ciloleucel)forCancer | Phase 1 | New Molecular Entity | Biologic |
PF-06647020 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: protein tyrosine kinase 7 (PTK7) Targeted Cytotoxicity | Cancer (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06804103 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: HER2 Antibody Drug Conjugate | Cancer (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06821497 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: EZH2 inhibitor | Cancer | Phase 1 | New Molecular Entity | Small Molecule |
PF-06863135 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: BCMA-CD3 Bispecific Antibody | Multiple Myeloma (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06873600 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: CDK 2,4,6 inhibitor | Breast Cancer Metastatic | Phase 1 | New Molecular Entity | Small Molecule |
PF-06881894, a potential biosimilar to Neulasta® (Pegfilgrastim) Therapeutic Area: Oncology Phase:Registration Compound Type:Biosimilar Business Segment: Biopharma Mechanism of Action: Human Granulocyte Colony Stimulating Factor | Neutropenia in patients undergoing cancer chemotherapy (Biosimilar) (E.U.) | Registration | Biosimilar | Biosimilar |
PF-06936308 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Vaccine Business Segment: WRDM Mechanism of Action: Therapeutic Vaccine | Multiple Cancers | Phase 1 | New Molecular Entity | Vaccine |
PF-06939999 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: protein arginine methyltransferase 5 (PRMT5) Inhibitor | Solid Tumors | Phase 1 | New Molecular Entity | Small Molecule |
PF-06940434 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: Integrin alpha-V/beta-8 Antagonist | Solid Tumors (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06952229 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: transforming growth factor, beta receptor 1 (TGFBR1) Inhibitor | Cancer | Phase 1 | New Molecular Entity | Small Molecule |
PF-07062119 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: GUCY2c CD3 Bispecific Antibody | Solid Tumors (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-07104091 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: CDK2 Inhibitor | Breast Cancer Metastatic
Project advanced | Phase 1 | New Molecular Entity | Small Molecule |
PF-07220060 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: CDK4 Inhibitor | Breast Cancer Metastatic
Project advanced | Phase 1 | New Molecular Entity | Small Molecule |
PF-07265807 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: AXL/MERTK Inhibitor | Solid Tumors
Project advanced | Phase 1 | New Molecular Entity | Small Molecule |
sasanlimab (PF-06801591) + Bacillus Calmette-Guerin (BCG) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti-PD-1 | Non-Muscle-Invasive Bladder Cancer (Biologic) | Phase 3 | New Molecular Entity | Biologic |
Talzenna (talazoparib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: PARP inhibitor | Combo w/ Xtandi (enzalutamide) for 1st Line Metastatic Castration-Resistant Prostate Cancer | Phase 3 | Product Enhancement | Small Molecule |
Talzenna (talazoparib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: PARP inhibitor | 2nd Line Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Product Enhancement | Small Molecule |
Talzenna (talazoparib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: PARP inhibitor | Germline BRCA Mutated Locally Advanced Triple Negative Breast Cancer | Phase 2 | Product Enhancement | Small Molecule |
Xtandi (enzalutamide) Therapeutic Area: Oncology Phase:Registration Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: Androgen receptor inhibitor | Metastatic Castration Sensitive Prostate Cancer (E.U.) | Registration | Product Enhancement | Small Molecule |
Xtandi (enzalutamide) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: Androgen receptor inhibitor | Non-metastatic High Risk Castration Sensitive Prostate Cancer | Phase 3 | Product Enhancement | Small Molecule |
